These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 10945013)

  • 1. [Concurrent chemoradiotherapy for T4 and/or M1 LYM squamous cell carcinoma of the esophagus].
    Miyata Y; Seki S; Ohtsu A; Kaneko K; Nakamura A
    Gan To Kagaku Ryoho; 2000 Jul; 27(8):1174-9. PubMed ID: 10945013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus.
    Ohtsu A; Boku N; Muro K; Chin K; Muto M; Yoshida S; Satake M; Ishikura S; Ogino T; Miyata Y; Seki S; Kaneko K; Nakamura A
    J Clin Oncol; 1999 Sep; 17(9):2915-21. PubMed ID: 10561371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
    Ishida K; Ando N; Yamamoto S; Ide H; Shinoda M
    Jpn J Clin Oncol; 2004 Oct; 34(10):615-9. PubMed ID: 15591460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
    Choi N; Park SD; Lynch T; Wright C; Ancukiewicz M; Wain J; Donahue D; Mathisen D
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):111-22. PubMed ID: 15337546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent chemoradiotherapy or endoscopic stenting for advanced squamous cell carcinoma of esophagus: a case-control study.
    Wong SK; Chiu PW; Leung SF; Cheung KY; Chan AC; Au-Yeung AC; Griffith JF; Chung SS; Ng EK
    Ann Surg Oncol; 2008 Feb; 15(2):576-82. PubMed ID: 18057993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late course accelerated hyperfractionated radiotherapy plus concurrent chemotherapy for squamous cell carcinoma of the esophagus: a phase III randomized study.
    Zhao KL; Shi XH; Jiang GL; Yao WQ; Guo XM; Wu GD; Zhu LX
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1014-20. PubMed ID: 15990003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer.
    Kim DW; Blanke CD; Wu H; Shyr Y; Berlin J; Beauchamp RD; Chakravarthy B
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):397-404. PubMed ID: 17097833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck.
    Katori H; Tsukuda M; Taguchi T
    Cancer Chemother Pharmacol; 2007 May; 59(6):789-94. PubMed ID: 17053926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent chemotherapy and radiation therapy for locally advanced carcinoma of the esophagus.
    Ohtsu A; Yoshida S; Boku N; Fujii T; Miyata Y; Hosokawa K; Koba I; Shimizu W; Ogino T
    Jpn J Clin Oncol; 1995 Dec; 25(6):261-6. PubMed ID: 8523823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
    Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
    J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck.
    Hitt R; Jimeno A; Millán JM; Castellano D; Cortés-Funes H
    Cancer; 2004 Aug; 101(4):768-75. PubMed ID: 15305408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-institute phase I/II trial of alternating chemoradiotherapy with 5-FU and nedaplatin for esophageal carcinoma.
    Kodaira T; Fuwa N; Kamata M; Furutani K; Tachibana H; Yamazaki T
    Anticancer Res; 2006; 26(1B):471-8. PubMed ID: 16739307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective dose escalation of chemoradiotherapy for esophageal cancer: role of treatment intensification.
    Seung SK; Smith JW; Molendyk J; Bader SB; Phillips M; Regan J; Louie J; Soo E; Seligman M; Ruzich J; Skokan L; Ross HJ
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):13-9. PubMed ID: 15726517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent chemoradiotherapy for esophageal cancer with malignant fistula.
    Koike R; Nishimura Y; Nakamatsu K; Kanamori S; Shibata T
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1418-22. PubMed ID: 18234437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
    Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus.
    Ishikura S; Nihei K; Ohtsu A; Boku N; Hironaka S; Mera K; Muto M; Ogino T; Yoshida S
    J Clin Oncol; 2003 Jul; 21(14):2697-702. PubMed ID: 12860946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoradiotherapy for T3 and T4 squamous cell carcinoma of the esophagus using low-dose FP and radiation: a preliminary report.
    Fujiwara Y; Kamikonya N; Inoue T; Koishi K; Yoshikawa R; Nakao K; Yagyu R; Nishiwaki M; Fujiwara M; Kojima S; Nakagawa K; Yamamura T
    Oncol Rep; 2005 Nov; 14(5):1177-82. PubMed ID: 16211282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.